Download MendeleyIdentification and development of a subtype-selective allosteric AKT inhibitor suitable for clinical development.
Page, N., Wappett, M., O'Dowd, C.R., O'Rourke, M., Gavory, G., Zhang, L., Rountree, J.S.S., Jordan, L., Barker, O., Gibson, H., Boyd, C., Feutren-Burton, S., McLean, E., Trevitt, G., Harrison, T.(2022) Sci Rep 12: 15715
- PubMed: 36127435
- DOI: https://doi.org/10.1038/s41598-022-20208-5
- Primary Citation of Related Structures:
8Q61 - PubMed Abstract:
The serine/threonine protein kinase AKT plays a pivotal role within the PI3K pathway in regulating cellular proliferation and apoptotic cellular functions, and AKT hyper-activation via gene amplification and/or mutation has been implicated in multiple human malignancies. There are 3 AKT isoenzymes (AKT1-3) which mediate critical, non-redundant functions. We present the discovery and development of ALM301, a novel, allosteric, sub-type selective inhibitor of AKT1/2. ALM301 binds in an allosteric pocket created by the combined movement of the PH domain and the catalytic domain, resulting in a DFG out conformation. ALM301 was shown to be highly selective against a panel of over 450 kinases and potently inhibited cellular proliferation. These effects were particularly pronounced in MCF-7 cells containing a PI3KCA mutation. Subsequent cellular downstream pathway analysis in this sensitive cell line revealed potent inhibition of pAKT signalling up to 48 h post dosing. ALM301 treatment was well tolerated in an MCF-7 xenograft model and led to a dose-dependent reduction in tumour growth. Enhanced efficacy was observed in combination with tamoxifen. In summary, ALM301 is a highly specific AKT 1/2 inhibitor with an excellent pharmacological profile suitable for further clinical development.
Organizational Affiliation:
Almac Discovery Ltd, Health Sciences Building, 97 Lisburn Road, Belfast, BT9 7AE, Northern Ireland, UK.
